Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. - Wikidata - awgldk - TriplyDB

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

http://www.wikidata.org/entity/Q33658659

about

Novel immunotherapeutic strategies of gastric cancer treatment Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer Consumer beware: a systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.Capecitabine in gastric cancer.Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status.Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).The role of taxanes in the management of gastroesphageal cancer Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.Elemental diet plus glutamine for the prevention of mucositis in esophageal cancer patients receiving chemotherapy: a feasibility study Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma New and emerging combination therapies for esophageal cancer.Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial.Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).Management of advanced gastric cancer.Optimal chemotherapy for advanced gastric cancer: is there a global consensus?Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.Chemotherapy for advanced gastric cancer.Capecitabine for the treatment of gastric cancer.Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma.What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy?Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience.A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and met Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.

P2860

Q27011232-06510B58-0603-466B-BE05-FA11B343CFE5 Q27028095-DC862F23-0971-4373-A62D-B5EA57139F03 Q28082921-855F0722-97F5-48B3-8289-989B756031A7 Q28740828-D6C35C77-462D-4553-9750-6CBE0C91B08B Q33403949-2D4107B7-3A80-487E-9B3A-E16999D9B5CA Q33991617-FD14DC1F-A983-4969-9AE2-0773EDE86920 Q34010159-24BF7470-1CD9-4BE5-A692-6A4338DE0AA3 Q34236005-051FD2CB-FBF4-4DD7-9C47-D4602B4AF22C Q34447512-ADD11A5A-E3C2-417C-ACD3-0B85537C64F6 Q34658209-32CC2B82-10E1-49C1-85BB-86A7898077CC Q34852173-7D308EFB-9271-4CAC-AD9A-564AF6D3FFDA Q35208094-38B24B87-C69B-4F9A-AD22-5D51131AEFF6 Q35713647-AAB043FF-F3D1-4B56-BA71-66068A235F64 Q36097240-330BA788-6F25-4B81-BFEE-D741F46DAC05 Q36117215-505C4181-7F98-4F96-9EF0-B4FF9F59BCBA Q36220464-E7C03154-CE5D-4568-81AA-1C08FAD35CF4 Q36396339-802ED9A7-FDCF-4EC0-B287-8C950CA232E2 Q36400298-9B99836E-6256-495F-828D-EA67B5BCE387 Q36661984-8620B1B5-6A9F-4E7A-9104-314670A5A007 Q36891363-6935C31E-EE2E-4DB1-A354-31F56E679232 Q36940910-A8F2C650-F355-48DE-9122-67B78EB5508A Q36996728-011DD690-A225-4350-9BA5-B6AE93277A92 Q37142445-E1D93C2C-1D6D-49B4-A9A4-93C56A2F66B7 Q37153952-8777F432-DED1-42F9-990C-0173D6586C32 Q37205013-2132A077-37DF-4ED0-BA4B-21E5FE572E75 Q37491365-32677836-04D0-4014-8DBB-21B175EEBDA6 Q37989161-6633B20D-2EFA-4CC0-B351-84DFC17F9F2C Q38139297-BC386846-3EFB-455E-94D2-6288C3A1D1E4 Q38542060-B0CD80FF-BA61-444E-BC1F-4B52B2252DF7 Q38604012-6CA48504-8CF4-42F9-8925-8A318B4E74A5 Q38608072-74749B19-49D0-4598-B420-992795ABBB0E Q38794776-3D49D1F0-AE79-41EB-8F28-186DE78915FC Q38998520-485674DB-9EE2-4157-B2F2-BA56A9898036 Q39015041-B12C5423-6BD6-4B6F-AA79-22992DB4A849 Q39682966-6A37602B-E8E7-4B5F-AF38-5E3370102DC9 Q39778923-C3E16C6E-53CD-47E8-87FB-4CB91675E910 Q40083161-DA2A7530-5BC2-4C57-BB9C-52A1DCE32C4F Q40315009-4BCAB8B6-5B0B-40F6-967B-EB9457FA33E9 Q41488053-05919EFE-3A6E-4527-B9FB-34B44FA82FF4 Q41503961-B0F843F3-5EB3-4AB1-9948-ADDDFBEB6C7E

P2860

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

http://www.wikidata.org/entity/Q33658659

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Randomised, non-comparative ph ...... cancer: the AGITG ATTAX trial.

@ast

Randomised, non-comparative ph ...... cancer: the AGITG ATTAX trial.

@en

type

label

Randomised, non-comparative ph ...... cancer: the AGITG ATTAX trial.

@ast

Randomised, non-comparative ph ...... cancer: the AGITG ATTAX trial.

@en

prefLabel

Randomised, non-comparative ph ...... cancer: the AGITG ATTAX trial.

@ast

Randomised, non-comparative ph ...... cancer: the AGITG ATTAX trial.

@en

P1433

Q33658659-15475525-7E49-41C2-A319-5C38070F6AC1

P1476

Q33658659-5D151336-FA1D-4718-B830-CCEF485F9A7B

P2093

Q33658659-0CC196C7-0D6A-4F7B-A8C0-9178A06055A7

Q33658659-298FD5A1-E82B-4286-97A3-0C2A9348AD92

Q33658659-2B306B2B-9331-4E46-829C-713D2FAB0E2F

Q33658659-389FFA67-6A9F-4D5D-88A9-BEA8C924D376

Q33658659-4C6A7EB2-A352-48CC-AA60-E96FE65D4908

Q33658659-57EE4541-2FB2-4C01-8F2A-68AD6EFE6820

Q33658659-724B8A46-D7F5-46F8-8D46-DAC1F11F6ACF

Q33658659-7A397A91-8D52-4CDA-B86F-3434400F1316

Q33658659-8B53AD67-F983-4A58-9E60-DDB0E23E99C7

Q33658659-BA039359-E561-496A-A7C6-314B2E9A2069

P2860

Q33658659-14585EC0-8F90-4204-A956-A39A195DA315

Q33658659-14FA2572-B866-482A-A875-247DC75AB6D8

Q33658659-420E0B59-6851-405B-9677-6E39AE7006C4

Q33658659-4435AC9D-DFA8-4C00-BD45-4D2CEFB7CA80

Q33658659-46F7B79E-92B2-4D39-9774-FA9477F35791

Q33658659-4995FD0C-44E2-4178-9EFB-33C44D29D91C

Q33658659-5903E75A-12C6-4AC0-95BA-05F90D00D7A9

Q33658659-757577EB-7BB8-4778-914A-B55680ACDFC8

Q33658659-781C321F-A0F5-4DFE-B552-DCED45C4D827

Q33658659-80BE4AA0-238D-4667-89C6-6D2AC53DC70C

P2888

Q33658659-9839B313-6172-435C-B8E9-E80520063F1E

P304

Q33658659-5D8B201C-E18A-487B-AC49-36A9EDAABBA0

P31

Q33658659-FAAB1586-7230-49A8-B52C-20D038FF7843

P356

Q33658659-16FC437E-1617-4C60-B39C-B04810F8B69A

P407

Q33658659-7ADE0167-99DE-439B-8E3F-970C4ACB13AE

P433

Q33658659-EC94A49C-76DE-43DE-A317-F26AC1D337EE

P478

Q33658659-E986217E-3CFB-4FC0-9114-32BB398176DF

P577

Q33658659-85718E3C-984C-449C-94A1-6271F4CDCB21

P5875

Q33658659-6773513D-54E4-470C-B53B-923CB634481C

P6179

Q33658659-72AF0F9D-DDA6-4B4F-AA48-26A973502113

P698

Q33658659-D1C469C9-B45A-4604-B8CD-87ADAE5763A2

P921

Q33658659-45CD2C2D-B421-4238-A04C-D7093F02BB23

P932

Q33658659-8AE0651B-6E7E-4006-B441-0FCD9EC98E85

P356

P1433

British Journal of Cancer

P1476

Randomised, non-comparative ph ...... cancer: the AGITG ATTAX trial.

@en

P2093

A Strickland

http://www.w3.org/2001/XMLSchema#string

Australasian Gastro-Intestinal Trials Group

http://www.w3.org/2001/XMLSchema#string

D Gibbs

http://www.w3.org/2001/XMLSchema#string

G Van Hazel

http://www.w3.org/2001/XMLSchema#string

J Zalcberg

http://www.w3.org/2001/XMLSchema#string

M M Cummins

http://www.w3.org/2001/XMLSchema#string

M Stockler

http://www.w3.org/2001/XMLSchema#string

N C Tebbutt

http://www.w3.org/2001/XMLSchema#string

T Sourjina

http://www.w3.org/2001/XMLSchema#string

V Ganju

http://www.w3.org/2001/XMLSchema#string

P2860

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Docetaxel administration schedule: from fever to tears? A review of randomised studies.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

P2888

P304

475-481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605522

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41001193

http://www.w3.org/2001/XMLSchema#string

P6179

1013409366

http://www.w3.org/2001/XMLSchema#string

P698

20068567

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2822950

http://www.w3.org/2001/XMLSchema#string